EBS - Emergent BioSolutions Trailing Twelve Months Revenue Growth

Brandmark of Emergent BioSolutions (EBS)

Emergent BioSolutions is reducing its reliance on government contracts by expanding into the retail pharmaceutical market, while antidote sales help mitigate liquidity shortages. Year-over-year sales dynamics over the last four quarters confirm these trends, where -18.00 characterizes this valuation parameter. The reliability of emergency biological delivery systems remains a critical factor for ensuring national security.

EBS - Emergent BioSolutions Inc. Sales Growth YoY (TTM) over the range 02/11/2024 - 11/16/2026

Summary analytical data breakdowns for Emergent Corp (EBS)

- current quotes and average value forecast:
Fundamental company valuation:Emergent BioSolutions EBS
Manufactured product of Emergent BioSolutions Inc

This indicator measures rolling year revenue dynamics, allowing investors to assess the actual pace of business expansion without seasonal distortions. By analyzing the current sales growth rate over a rolling 12-month period year-over-year on the GURU.Markets platform, one can differentiate systemic demand from one-off contracts, which is critical for the monopolist Emergent BioSolutions (EBS), which possesses exclusive pricing power over strategic antidotes.